OLMA insider trading
HealthcareOlema Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Company website: olema.com
OLMA insider activity at a glance
FilingIQ has scored 275 insider transactions for OLMA since Jun 15, 2020. The most recent filing in our index is dated Apr 28, 2026.
Across the full history, 24 open-market purchases
and 129 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on OLMA insider trades is 58.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest OLMA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding OLMA
Frequently asked
- How many insider trades does FilingIQ track for OLMA?
- FilingIQ tracks 275 Form 4 insider transactions for OLMA (Olema Pharmaceuticals, Inc.), covering filings from Jun 15, 2020 onwards. 9 of those were filed in the last 90 days.
- Are OLMA insiders net buyers or net sellers?
- Across the full Form 4 history for OLMA, 24 transactions (9%) were open-market purchases and 129 (47%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OLMA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is OLMA in?
- Olema Pharmaceuticals, Inc. (OLMA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.81B.
Methodology & sources
Every OLMA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.